The federal government is winding down a multibillion-dollar program that has quietly held down Medicare Part D drug premiums, a shift that could push monthly costs higher for millions of enrollees when 2027 coverage begins. The Centers for Medicare & Medicaid Services has confirmed that the Part D Premium Stabilization Demonstration will close at the end of 2026 rather than continue into next year. Final 2027 premiums are not fixed yet, but the removal of a federal cushion that absorbed part of the yearly increase sets up a harder line on drug-plan bills for the coming enrollment season.
How the Part D stabilization subsidy held premiums down
The demonstration was created to soften a wave of premium increases tied to the Inflation Reduction Act’s redesign of Part D, which capped annual out-of-pocket drug spending and pushed more catastrophic-cost liability onto insurers. In exchange for federal payments, participating plans agreed to limit how far their premiums could rise from one year to the next. Nearly every plan sponsor signed on. For beneficiaries, the effect showed up as flat or modest premium changes, with little sign that a temporary subsidy was doing much of the work behind the scenes.
Government estimates put the cost of the demonstration at roughly $9.8 billion across 2025 and 2026, and CMS has said insurers now have enough experience with the redesigned benefit to price plans without it, according to reporting on the agency’s decision. Without the program last year, average monthly premiums for people who stayed in their 2024 plan would have nearly doubled. That figure is a rough measure of how much of the true cost the subsidy was masking, and how much could resurface once the payments stop.
Free retirement updates: A quiet rule change can shrink your Social Security or Medicare check, and no one warns you. The free Retirement Shield newsletter catches these early and tells you what to do. Get it free.
Why 2027 drug-plan premiums are set to climb
With the subsidy gone, the redesigned benefit’s higher baseline costs land more directly on plans, which generally means one of a few outcomes: higher premiums, thinner benefits, or insurers pulling certain plans from the market. CMS set the 2027 national average monthly bid amount at $296.05 and the national base beneficiary premium at $41.33, the starting figure used to calculate each plan’s basic premium rather than the final charge any one person pays. The real bills vary by plan and region.
CMS frames the wind-down as the scheduled end of a temporary demonstration rather than a benefit cut, and the agency plans to publish final 2027 premiums in the fall before enrollment opens. For a household living on a fixed income, the label matters less than the number. An expiring subsidy and a higher monthly bill produce the same result at the pharmacy counter, and standalone drug-plan members are the group most exposed, since the demonstration was aimed squarely at their premiums.
The premium is only one piece of a Part D bill. Deductibles, the specific drugs a plan covers, and pharmacy networks all move each year, so a plan that advertises a lower premium can still cost more once a particular prescription is priced in. The end of the stabilization payments raises the chance that the plan a person carries in 2026 is no longer the best value in 2027, which is exactly the comparison the annual enrollment period is designed to force.
What the fall enrollment window lets beneficiaries do
Medicare’s Annual Enrollment Period runs from October 15 to December 7 and is the main yearly chance to change or switch a Part D or Medicare Advantage drug plan for the coming year, with new coverage taking effect January 1. Because 2027 premiums are due to be published in the fall, enrollees should have real figures in hand before the window closes. That timing makes a plan-by-plan comparison the single most useful step for anyone worried about a premium jump.
Comparing plans on total expected annual cost, not premium alone, is what protects a budget when a subsidy disappears. Medicare’s Plan Finder lets a person enter current prescriptions and see each plan’s projected yearly cost, including premium, deductible, and drug-specific pricing. For someone on an expensive medication, a plan with a higher premium can still be cheaper across twelve months, and the opposite pairing is just as common.
There is also a backstop for lower-income beneficiaries. The Part D Low-Income Subsidy, known as Extra Help, covers much or all of the premium and drug costs for people below certain income and asset limits, and recent expansions widened who qualifies. Anyone near those thresholds who has never applied has reason to check before 2027 pricing takes hold, because the subsidy can offset much of any premium increase the demonstration’s end may bring.
The unresolved question is whether the end of the stabilization demonstration is a one-year correction or the leading edge of steeper increases as the Part D redesign fully phases in. CMS has not signaled a replacement cushion, and the cost pressures that made the subsidy necessary do not ease in 2027. For the millions whose premiums the program touched, the fall premium release will be the first hard evidence of how much of that buffer they were leaning on, and how much of it they are about to pay themselves.
This article was produced with AI assistance and reviewed against primary sources by The Money Overview editorial team.
More Financial Reading
